Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Model system identifies new FHV-1 drug
Black cat eye
The team identified the drug while developing a model to test drugs that treat feline eye infections.

Raltegravir requires only once-a-day dosing

A model system developed to test medication for feline herpesvirus 1 (FHV-1) has identified a new drug that only needs to be applied once-a-day.

Identified by scientists at Cornell's College of Veterinary Medicine, raltegravir is used in humans to treat HIV infections, but it had never been used to treat FHV-1 in cats.

“We found that it is very effective against FHV-1. It even worked when we applied the drug only once every 24 hours,” says study leader Dr Gerlinde Van de Walle.

The team identified the drug while developing a model to test drugs that treat feline eye infections.

Described in the Journal of General Virology, the new model used corneas donated from cats that died of causes other than eye disease. Researchers say this method offers a better reflection of what happens in the eyes of a cat, than models consisting of cells in a petri dish.

In the study, the team applied the FHV-1 virus to some of the corneas and tested the effectiveness of two commonly prescribed drugs: cidofovir and acyclovir.

Both drugs cleared the infection when applied every 12 hours, but cidofovir was more effective.

The team then used the model system to test raltegravir. They found that it was just as effective as other drugs for treating FHV-1 infections and only needed to be administered once a day.

Dr Walle says that she eventually hopes to see the drug tested in a well-controlled clinical trial.

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.